Oncoinvent (ONCIN)

[Ceara]

Stemmer det at vi kan vente nye svar på avlesninger nå i juni og melding om eventuell fullført innrullering i september?

[hybrid]

1. CRC data en gang i løpet av juni regnes det med.
2. Heller tvilsomt gitt hastigheten i børjan, men vi får nok en oppdatering rundt rekruttering i august.

Fullført rekruttering i september hadde blåst fletta av de fleste tror jeg.

[InVivo]

@hybrid

Fullført rekruttering i september hadde blåst fletta av de fleste tror jeg.

Totalt urealistisk ja, men om de hadde klart det så burde vi snakket mcap på 2-3 milliarder.

Tror de hadde en veldig bra rekruttering i extension studiet, fikk vel inn ca 36 pax på litt over 12 mnd. Så det burde jo være mulig å komme relativt raskt i mål med 12 aktive sentre.

Mitt personlige håp er at de bruker CRC for å lokke partner ombord. Videre studier her står jo på hold på grunn av mangel på kapital. Kapital er jo ikke et problem for BP, så her burde jo det være mulig å komme til en enighet med f.eks. Bayer

[InVivo]

Greit å huske på at Nano var priset til ca 5 milliarder når de hadde omtrent samme datapakke som Oncoinvent vil ha etter dataslipp i CRC😏

Så det ligger vel an til en heftig reprising hvis dataslippet blir like bra som det vi har sett hittil

[hybrid]

Verdt å merke seg at det var to år før fase 2b studiet var startet.

Med tanke på studieløpet i forhold til oncoinvent var ikke nano i nærheten engang.

To randomiserte studier, hvor ett er i gang, og vi vaker rundt 150-200mill i mcap.

Får håpe at effektsignalet fra de resterende pasientene er uendret i forhold til de allerede avleste.

[Tixis]

Ferie penger snart. Lurer på å kjøpe litt mer eller om d er lurt å vente å se om det kommer en grise emi til på kr 1.
Hva tenker andre her som har litt midler og kanskje vurderer mere kjøp?
Jeg har ikke så mye, men har 50k på snitt 2.4
Lurer på å ta 10k til.
Går dette veien så kan dette bli riktig så lukrativt på sikt, men har jo NN i bakhodet hvor jeg svei av 1.2 mill
Huff og huff

[Pk2k]

Alt avhenger av fremgang, selskapet har valgt å ikke oppdatere på kvartal pres (Innrullering hastighet). Ifb med overnevnte, ikke invester mer enn du har råd til å tape

Ps, mistenker delay i innrulleringen men det gjenstår å se, jeg er ute atm men ser etter ny inngang på krona eller neste emisjon.

Nye oppdaterte data kan selfølgelig slå andre veien, kan lett bli stående igjen på perrongen.

[Tixis]

I denne har jeg tenkt at d får briste eller bære. Dermed har jeg råd til å tape, men kanskje jeg bare lar d være med det jeg har og så får d bare gå som d går.

Men har bestemt meg for en ting og d er at går dette til hælvete så blir d aldri mere biotek for meg.
Bortsett fra at jeg har litt PHO da som skal få stå å kose seg til 100 lappen i alle fall

[InVivo]

@Tixis

Ferie penger snart.

@Pk2k

kan lett bli stående igjen på perrongen.

Får vi et nytt fenomen her? Feriepengerally

[Tixis]

Slik jeg har forstått det på noen her inne så skal det tilkomme ytterligere pasient resultater nå i sommer eller tidlig høst.
Avlesning så langt har jo vært gode, selv om d er snakk om få pasienter.

Kan man tenke seg at ett eller annet BP selskap har en muntlig avtale om en skriftlig avtale så snart de siste avlesningene er i boks, og at de er konsistente med d som allerede er levert?

[InVivo]

@Tixis

Kan man tenke seg at ett eller annet BP selskap har en muntlig avtale om en skriftlig avtale

Som en smart fyr en gang skrev på TI, ‘‘kan’’ er et fint ord

[Ratzeputz]

Stille før stormen her i Oncoinvent😉

Kjøpte 19000 aksjer i mårrest, og la inn ordre på 36000 nye aksjer nå på 1,9380,- fikk nesten alle…

Kommer snart kliniske data her! Jeg går for gode tall og kursoppgang🚀

Å kjøpe Oncoinvent på dette nivået bør man bare benytte seg av.
Er et gigantisk potensial, og det de har levert av data så langt er meget lovende!

[hybrid]

BNMS Awards & Prize Winners 2025

[urban66]

Et team fra Imperial College Healthcare NHS Trust i London har vunnet en pris for deres presentasjon om "Tidlige erfaringer med intraperitoneal α-utslippende radionuklidterapi (Radspherin®) hos pasienter med primær avansert epitelial kreft med peritoneale metastaser; en leges perspektiv. " Ikke bare bruker uavhengige kreftleger Radspherin allerede, de får anerkjennelse for resultatet. Fest setebeltene

[TekBot]

Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent’s novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer

Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, is thrilled to announce positive topline data from the Phase 1/2a clinical trial (RAD-18-002) evaluating Radspherin® in patients with peritoneal metastases originating from colorectal cancer.
…

Vis børsmeldingen

Reducing peritoneal recurrence in colorectal cancer is critically important because peritoneal metastases are associated with a particularly poor prognosis and significantly lower overall survival compared to other forms of recurrence . The development of peritoneal metastases is not only linked to worse survival, but also to distressing symptoms, making disease management more challenging and often resulting in treatment interruptions and repeated hospitalizations.

Standard therapies for peritoneal metastases are limited, and the only treatment option with curative intent is surgery, which aims to remove as much tumor as possible in the peritoneal cavity. However, surgical resection leaves behind microscopic deposits of cancer cells, giving rise to new peritoneal metastases and disease progression. Radspherin®, direct intraperitoneal targeting with the alpha-emitter radium-224, aims to eliminate these post-surgery micro-metastases and thereby prevent or delay peritoneal recurrence.

In this single-arm trial of 47 patients, 36 received Radspherin® at a 7 MBq dose. The primary endpoint—peritoneal recurrence-free survival (pRFS)—yielded remarkable results:

• Only 27.8% (10 of 36) experienced peritoneal disease recurrence at 18 months, a marked reduction compared to published data for standard of care, where approximately 50% of patients typically see peritoneal recurrence at this stage
• At 18 months, 61.1% (22 of 36) of patients had experienced any recurrence, but notably, just 22.7% (5 of 22) had peritoneum as the first site of recurrence
• Final data from all 47 treated patients across dose levels further reinforce the favorable safety profile of Radspherin®

Additional results will be published upon completion of the full dataset analysis.

"It’s highly encouraging to see patients treated with Radspherin® achieving outcomes that exceed expectations for this challenging population. As a clinician, I’m hopeful that this promising therapy will become an option I can offer to future patients in need,” said Dr. Stein Gunnar Larsen, Principal Investigator at the Oslo University Hospital, Norway.

Prof. Dr. Wilhelm Graf, Principal Investigator at Uppsala University Hospital, Sweden, added: “Colorectal peritoneal metastases present a major therapeutic challenge with limited effective options, and these findings support the potential of a novel approach that demonstrates both clinical promise and a favorable safety profile.”
”We are inspired and motivated by these compelling data. They reinforce our belief in Radspherin®’s potential as a novel treatment targeting peritoneal metastases and justify continued advancement of the program,” said Oystein Soug, CEO of Oncoinvent. “We extend our deepest gratitude to the patients, investigators, and clinical teams who made this trial possible.”

Radspherin® is currently investigated in an ongoing phase 2 trial evaluating the treatment of peritoneal carcinomatosis from ovarian cancer. A positive safety review of the lead-in cohort was announced in Q1 2025, and the trial is currently recruiting patients according to plan in European and US sites in the randomized phase.

About RAD-18-002
RAD-18-002 was an open label Phase 1/2a trial conducted in patients with colorectal peritoneal metastases. The trial was designed to evaluate dosing, safety and tolerability, and signal of efficacy of intraperitoneally administered Radspherin® following complete surgical resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). A total of 47 patients were enrolled across sites in Norway and Sweden, with 36 patients receiving the recommended dose of 7 MBq.

About Radspherin®
Radspherin® is an investigational radiopharmaceutical designed for the local treatment of cancer that has spread to body cavities. It consists of calcium carbonate microparticles containing the radioactive material radium-224. The mode of action is the decay of radium-224 emitting alpha-particles, a highly potent form of ionizing radiation. Radspherin® is investigated in ongoing clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal cancer and it is administered intraperitoneally after surgical resection with removal of all macroscopic tumors.

About Oncoinvent
Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. In addition to the currently finalized phase 1/2a trial in colorectal cancer, one phase 1 trial and one randomized phase 2 trial, both in ovarian cancer, are ongoing in the US, UK and Europe. Preliminary clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The experienced Oncoinvent team runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth Oslo.

Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Oncoinvent ’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Oncoinvent’ s expectations as of the date of this press release, and Oncoinvent disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers.

For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com

Kilde

[Lucrum]

A positive safety review of the lead-in cohort was announced in Q1 2025, and the trial is currently recruiting patients according to plan

[Pk2k]

Kaldt på perrongen, lykke til på åpningen i dag folkens

[TekBot]

Oncoinvent (ONCIN): Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Oncoinvent ASA (OSE: ONCIN) a clinical stage radiopharmaceutical company developing innovative treatments for solid cancers, invites for a presentation of the top-line results from the Phase 1/2a clinical trial (RAD-18-002) evaluating Radspherin® in patients with peritoneal metastases originating from colorectal cancer.

A webcast will be held on June 18th 2025 at 13:00 CEST. A link to the webcast will be available for everyone to view on www.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar.
…

Vis børsmeldingen

About Oncoinvent
Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. In addition to the currently finalized phase 1/2a trial in colorectal cancer, one phase 1 trial and one randomized phase 2 trial, both in ovarian cancer, are ongoing in the US, UK and Europe. Preliminary clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The experienced Oncoinvent team runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth Oslo.

About Radspherin
Radspherin® is an investigational radiopharmaceutical designed for the local treatment of cancer that has spread to body cavities. It consists of billions of calcium carbonate microparticles containing the radioactive material radium-224. The mode of action is the decay of radium-224 emitting alpha-particles, a highly potent form of ionizing radiation. Radspherin® is investigated in ongoing clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal cancer and it is administered intraperitoneally after surgical resection with removal of all macroscopic tumors.

Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Oncoinvent’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Oncoinvent’s expectations as of the date of this press release, and Oncoinvent disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers.

For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com

Kilde

[InVivo]

@Lucrum

and the trial is currently recruiting patients according to plan

Viktig viktig!!!

[hybrid]

Hadde vært greit å visst hva planen var

Det sagt, med en slik ordlyd kan man ikke anta annet enn at de er i rute.